Mountain View, United States
Namocell is a biotechnology startup based in the United States that specializes in providing high-performance single cell sorting and dispensing systems. Founded in 2014, the company's slogan "The Fastest Way to Single Cells" underscores its commitment to enabling single cell research, therapeutics development, and diagnostics.
Their Single Cell Dispensers have gained recognition for being the fastest and easiest solution to identify and isolate various types of cells, including single cells, nuclei, protoplasts, bacteria, yeast, and fungi. Notably, these dispensers allow for single cell sorting and dispensing in a single step while ensuring the gentle treatment of cells to preserve their viability and integrity.
Namocell caters to a diverse range of applications, including cell line development and engineering, CRISPR and iPSC cloning, single cell genomics, cell and gene therapy, antibody discovery, rare cell isolation, single cell proteomics, and synthetic biology.
The company received its Series A investment on 01 May 2017, with the funding coming from Foothill Ventures. Those interested in learning more about Namocell's offerings or requesting a demo can visit their website at www.namocell.com.
